Braeburn Pharmaceuticals Camarus AB recently announced that its ongoing trial of injectable opioid dependence treatments has been a success. This therapy could be used to help address the growing problem of opioid dependency in the US.
Over 400 patients took part in the study, the intention of which was to investigate and assess the impact of an injectable buprenorphine formulation on individuals with a reliance on opioids, with the results revealing that the injection performs better than current formulations. The Wall Street Journal highlights the importance of the recent trial results, pointing out that nearly 50,000 people died in 2014 as a result of the opioid epidemic; in addition, 650,000 US citizens used buprenorphine for opioid addictions in the same year.
The CEO of Braeburn, Behshad Sheldon, announced that the company was pleased with the trial results and that the products represented a new and effective solution for affected patients and their doctors. He went on to highlight the growing problem of opioid addiction, stating that 2.6 million patients are currently known to be affected. The new treatment can be prescribed in either a weekly or monthly formulation and is available in a variety of dosages to suit differing patient needs.
An added complication in successfully treating patients addicted to opioids is that the individual’s needs tend to evolve over time. Patients initially require tailored treatment, then need to be stabilised, and finally move on to the long-term maintenance part of the treatment programme.
Results to be unveiled in 2017
The companies involved in the trial expect to submit the treatment for approval by regulators sometime around the middle of 2017. Companies and agencies that provide clinical trial services uphold strict standards to ensure the accuracy of results and safety of patients at all points of the trial. Once clinical trial services are complete and a trial has been found to have been a success, the next step is obtaining official approval from government and regulatory bodies before the drug or treatment can be made available to the general public and medical profession.
Sheldon announced that the company believed its CAM2038 treatments, along with previously approved products, could revolutionise opioid addiction treatments for patients and doctors. Researchers working on the trial found that adverse events were limited.